<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02011815</url>
  </required_header>
  <id_info>
    <org_study_id>BreastCA_circa_mech</org_study_id>
    <nct_id>NCT02011815</nct_id>
  </id_info>
  <brief_title>Exploring Biological Linkage Between Circadian Disruption and Cancer Progression</brief_title>
  <official_title>A Prospective Study of Exploring Possible Biological Linkage Between Circadian Disruption and Cancer Progression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the possible association between the circadian
      disruption and cancer progression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The biological markers that are assumed to bridge this association are measured and analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 10, 2013</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>3 years (and more) after recruitment</time_frame>
    <description>The data progression-free survival will be done by reviewing patients' medical record.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Circadian disruption</measure>
    <time_frame>Baseline, after 1 month, after 6 month, after 12 month</time_frame>
    <description>Morningness-Eveningness Questionnaire and Munich Chronotype Questionnaire will be used during assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective sleep cycle measures</measure>
    <time_frame>Baseline, after 1 month, after 6 month, after 12 month</time_frame>
    <description>The assessment will be performed by using actigraph and sleep diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physiological measures</measure>
    <time_frame>Baseline, after 1 month, after 6 month, after 12 month</time_frame>
    <description>The measures include blood pressure, body temperature, skin conductance, breathing pattern, and Electroencephalography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep quality measures</measure>
    <time_frame>Baseline, after 1 month, after 6 month, after 12 month</time_frame>
    <description>The measurements will be performed using Epworth sleepiness scale, Pittsburgh Sleep Quality Index, and Insomnia Severity Index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life measure</measure>
    <time_frame>Baseline, after 1 month, after 6 month, after 12 month</time_frame>
    <description>The measurement will be performed using M.D. Anderson Symptom Inventory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer related Fatigue</measure>
    <time_frame>Baseline, after 1 month, after 6 month, after 12 month</time_frame>
    <description>Fatigue severity scale will be used during the assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distress related measure</measure>
    <time_frame>Baseline, after 1 month, after 6 month, after 12 month</time_frame>
    <description>Hospital Anxiety and Depression Scale will be used during the assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Posttraumatic Stress-related symptom measure</measure>
    <time_frame>Baseline, after 1 month, after 6 month, after 12 month</time_frame>
    <description>Impact of Event Scale-revised will be used to categorize and quantify Posttraumatic stress-related symptom in cancer patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Menopausal symptom measure</measure>
    <time_frame>Baseline, after 1 month, after 6 month, after 12 month</time_frame>
    <description>Menopause Rating Scale will be used during the assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Personality measure</measure>
    <time_frame>Baseline</time_frame>
    <description>Temperament and Character Inventory will be used to examine the personality factor in each participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic polymorphism</measure>
    <time_frame>Baseline</time_frame>
    <description>Variable Number Tandem Repeat and Single Nucleotide Polymorphism of circadian-rhythm related genes will be examined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epigenetic Change</measure>
    <time_frame>Baseline</time_frame>
    <description>The methylation specific Polymerase Chain Reaction technique will be used to explore methylation patterns in circadian clock gene or in a global gene level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortisol level</measure>
    <time_frame>Baseline</time_frame>
    <description>Salivary cortisol level will be measured multiple times at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Melatonin</measure>
    <time_frame>Baseline</time_frame>
    <description>Salivary or Urine melatonin level will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>Baseline</time_frame>
    <description>The various inflammation markers will be measured from blood sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years (and more) after recruitment</time_frame>
    <description>The data progression-free survival will be done by reviewing patients' medical record.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">236</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Breast cancer</arm_group_label>
    <description>Diagnosed breast cancer patients who are getting chemotherapy for the first time.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, serum Saliva Urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        University (Tertiary) hospital, oncology clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18-70

          -  Breast cancer patients who are getting chemotherapy for the first time in life

          -  Patients are either having stage 4 cancer or starting neoadjuvant chemotherapy.

          -  Patient have signed on the informed consent, and well understood the objective and
             procedure of this study

        Exclusion Criteria:

          -  Patients already have received chemotherapy

          -  Patient had another cancer (except thyroid cancer) within 5 years

          -  Patient with severe medical condition

          -  Patient had taken psychiatric medication more than 1 month in life

          -  Patient worked the night shift for more than 1 month in 6 months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bong-Jin Hahm, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dooyoung Y Jung, M.D.</last_name>
    <phone>82220723767</phone>
    <email>dooyoung@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Jongno-gu</state>
        <zip>140-013</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dooyoung Y Jung, M.D.</last_name>
      <phone>82220723767</phone>
      <email>dooyoung@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Bong-Jin Hahm, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dooyoung Y Jung, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.snuh.org/</url>
    <description>study site webpage</description>
  </link>
  <link>
    <url>https://cris.snuh.org/ncris/</url>
    <description>Institutional Review Board</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2013</study_first_submitted>
  <study_first_submitted_qc>December 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2013</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast neoplasms</keyword>
  <keyword>Circadian rhythm</keyword>
  <keyword>sleep</keyword>
  <keyword>survival</keyword>
  <keyword>distress</keyword>
  <keyword>anxiety</keyword>
  <keyword>depression</keyword>
  <keyword>quality of life</keyword>
  <keyword>actigraph</keyword>
  <keyword>fatigue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

